Mostrar el registro sencillo del ítem
Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane
dc.creator | Spiliotaki M., Kallergi G., Nikolaou C., Xenidis N., Politaki E., Apostolaki S., Georgoulia N., Koinis F., Tsoukalas N., Hatzidaki D., Kotsakis A., Georgoulias V. | en |
dc.date.accessioned | 2023-01-31T10:01:21Z | |
dc.date.available | 2023-01-31T10:01:21Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1007/s00280-020-04227-5 | |
dc.identifier.issn | 03445704 | |
dc.identifier.uri | http://hdl.handle.net/11615/79331 | |
dc.description.abstract | Purpose: Detection of CTCs represents a poor prognostic factor in patients with early and metastatic breast cancer (mBC) and treatment with everolimus–exemestane (E/E) is an established effective treatment in hormone receptor-positive/HER2-negative mBC patients. The effect of E/E on CTCs in mBC patients was prospectively investigated. Methods: CTCs from 50 pre-treated patients with mBC receiving E/E were analyzed using the CellSearch (CS) platform and triple immunofluorescence (IF) staining for cytokeratin, M30 and Ki67 expression to assess their proliferative and apoptotic status. Results: CTCs (by CS) were detected in 64% of patients before treatment and E/E administration resulted in their decreased prevalence [(n = 18; 36%, p = 0.004) and (n = 7; 19.4%, p = 0.019) post-1st and post-3rd treatment cycle, respectively] whereas it was significantly increased at disease progression (PD: 61%) compared to post-1st and post-3rd cycle (p = 0.049 and p = 0.021, respectively). Ki67-positive CTCs were detected in 60%, 60%, 17% and 50% of patients before treatment, post-1st, post-3rd cycle and at PD, respectively, while the opposite was observed for M30-positive CTCs (0% at baseline, 10% after the 1st cycle, 50% after the 3rd cycle and 0% at PD). The detection of even ≥ 1 CTC/5 ml after one cycle was associated with decreased PFS (3.3 vs 9.0 months, p = 0.025) whereas the detection of even ≥ 2 CTCs at PD was associated with decreased OS (32.4 vs 19.5 months; p = 0.009). Conclusions: The combination of E/E resulted in early elimination of proliferating CTCs in mBC patients and this effect was associated with a favorable clinical outcome. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature. | en |
dc.language.iso | en | en |
dc.source | Cancer Chemotherapy and Pharmacology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099968992&doi=10.1007%2fs00280-020-04227-5&partnerID=40&md5=46348c7fe4e7a8b6bc293bed5af050df | |
dc.subject | cytokeratin | en |
dc.subject | cytokeratin 18 | en |
dc.subject | everolimus | en |
dc.subject | exemestane | en |
dc.subject | Ki 67 antigen | en |
dc.subject | phycoerythrin | en |
dc.subject | androstane derivative | en |
dc.subject | antineoplastic agent | en |
dc.subject | epidermal growth factor receptor 2 | en |
dc.subject | ERBB2 protein, human | en |
dc.subject | everolimus | en |
dc.subject | exemestane | en |
dc.subject | tumor marker | en |
dc.subject | adjuvant radiotherapy | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | apoptosis | en |
dc.subject | Article | en |
dc.subject | bone metastasis | en |
dc.subject | bone scintiscanning | en |
dc.subject | cancer hormone therapy | en |
dc.subject | cell proliferation | en |
dc.subject | cellular distribution | en |
dc.subject | circulating tumor cell | en |
dc.subject | clinical article | en |
dc.subject | clinical practice | en |
dc.subject | comparative study | en |
dc.subject | controlled study | en |
dc.subject | disease exacerbation | en |
dc.subject | drug efficacy | en |
dc.subject | female | en |
dc.subject | human | en |
dc.subject | human cell | en |
dc.subject | human epidermal growth factor receptor 2 negative breast cancer | en |
dc.subject | human epidermal growth factor receptor 2 positive breast cancer | en |
dc.subject | human tissue | en |
dc.subject | immunofluorescence | en |
dc.subject | MDA-MB-231 cell line | en |
dc.subject | nuclear magnetic resonance imaging | en |
dc.subject | overall survival | en |
dc.subject | partial mastectomy | en |
dc.subject | priority journal | en |
dc.subject | prospective study | en |
dc.subject | protein expression | en |
dc.subject | radical mastectomy | en |
dc.subject | salvage therapy | en |
dc.subject | SK-BR-3 cell line | en |
dc.subject | tumor volume | en |
dc.subject | visceral metastasis | en |
dc.subject | x-ray computed tomography | en |
dc.subject | breast tumor | en |
dc.subject | metabolism | en |
dc.subject | metastasis | en |
dc.subject | middle aged | en |
dc.subject | pathology | en |
dc.subject | prognosis | en |
dc.subject | salvage therapy | en |
dc.subject | treatment outcome | en |
dc.subject | tumor embolism | en |
dc.subject | very elderly | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Aged, 80 and over | en |
dc.subject | Androstadienes | en |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | en |
dc.subject | Biomarkers, Tumor | en |
dc.subject | Breast Neoplasms | en |
dc.subject | Everolimus | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Metastasis | en |
dc.subject | Neoplastic Cells, Circulating | en |
dc.subject | Prognosis | en |
dc.subject | Prospective Studies | en |
dc.subject | Receptor, ErbB-2 | en |
dc.subject | Salvage Therapy | en |
dc.subject | Treatment Outcome | en |
dc.subject | Springer Science and Business Media Deutschland GmbH | en |
dc.title | Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane | en |
dc.type | journalArticle | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |